PROGRAM

MASTERCLASS PRELIMINARY PROGRAM

Tuesday 24 March 2026

Tuesday 24 March 2026
0800

Registration opens and networking (including refreshments)

0845

Opening address

Prof Pali Thordarson, Director, RNA Institute

Session 1  0900 - 0945

Keynote Presentation

A snapshot of the global CGT landscape

Leah Goodman, CEO BioIntelect

Cell and Gene Therapy: Market, Science and Future Directions

  • An overview of the current state of advanced therapies worldwide, highlighting key scientific advances, market trends, and investment opportunities shaping the sector.
0945 - 1030

Keynote Presentation

Learnings from an Investor

John Ratcliffe, Chief Investment Officer, Altea Investments

 

Building the Infrastructure Enabling Tomorrow’s Therapeutics in APAC

  • How strategic investment in life sciences infrastructure is shaping the future of advanced therapies and positioning Asia-Pacific as a global hub.
1030 - 1100

Morning refreshments and networking

Session 2
1100 - 1130

IP in RNA vs Cell Therapies: What does a successful IP roadmap look like for both

Dr Peter Brown & Dr Malcom Lyons, Griffith Hack

1130 - 1200

From Prototype to GMP: Designing Scalable Equipment for Cell & Gene Therapy Manufacturing

Campbell Richard, Invetech

1200 - 1230

Key learnings from transporting MRNA vaccines. What should future businesses and startups need do right with logistics.

Brent McPherson, National Business Development Manager, Aus and NZ, World Courier

1230 - 1330

Lunch and networking

Session 3
1330 - 1400

Preparing for clinical trials for cell therapies vs RNA therapies. Patient vs data. How much, how long?

Dr Robert Lin, CEO, GreenLight Clinical

1400 - 1430

Cell and gene therapies: Physician panel’s perspective and how to engage with key opinion leaders 

Moderator: Leading physician

Prof James Chong, Westmead Hospital

Prof Anthony Kelleher, St Vincent’s Sydney

Prof Michelle Farrar, Sydney Children's Hospital

1430 - 1500

Session to be announced

1500 - 1530

Afternoon refreshments, Networking, Announcements

Session 4
1530 - 1600

Company Experience: EOSGene

Dr Yagiz Alp Aksoy, Co-Founder/ Director, EOSGene

1600 - 1630 

Panel discussion: FDA Roundtable on Cell and Gene Therapy in June 2025 revealed that the US is facing many similar challenges as we do in Australia. Can Australia do things differently to get ahead? 

1630 - 1645

Closing address: Silvio Tiziani, CEO, CCRM Australia

WITH THANKS TO

FOR ENQUIRIES, CONTACT LEISHMAN ASSOCIATES

227 Collins Street, Hobart, TAS 7000

P: +61 3 6234 7844

E: conference@leishman-associates.com.au